2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1505

The Biosimilar Landscape: A Systematic Review of Its Current Status
Abstract Number: 1811

The Burden of Depression on Healthcare Utilization in a Population-Based Cohort of Patients with Systemic Lupus Erythematosus
Abstract Number: 2656

The Burden of Neuropsychiatric Symptoms in Systemic Lupus Erythematosus: Physician’s and Patient’s Perspectives
Abstract Number: 343

The Caspase 8/RIPK3 Signaling Axis Has Opposing Roles in Myeloid and Dendritic Cells during Progression of a Murine Model of Acute Inflammatory Arthritis
Abstract Number: 2865

The Cellular Effects of ANTI-Factor Xa Antibodies Isolated from Patients with Antiphospholipid Syndrome ARE Inhibited By Factorxa Inhibitors, Hydroxychloroquine and Fluvastatin
Abstract Number: 2881

The Center of Excellence in Musculoskeletal Care and Education: A Sustainable Interprofessional, Multidisciplinary Programmatic Innovation Developed with the Department of Veterans Affairs
Abstract Number: 2914

The Clinical and Radiographic Course of Early Undifferentiated Arthritis Under Treatment Is Not Dependent on the Amount of Erosions at Diagnosis. Results from the Swiss Prospective Observational Cohort
Abstract Number: 2749

The Clinical Course of Acute Deep Vein Thrombosis of the Legs in Behçet’s Syndrome
Abstract Number: 1659

The Clinical Relevance of a Repeat Biopsy in Lupus Nephritis (LN) Flares
Abstract Number: 593

The Clinimetric Outcomes of Two Bath Ankylosing Spondyltis Metrology Indices in Treatment with TNF-á Blockers
Abstract Number: 1821

The Co-Occurrence Patterns of MRI Lesions and Incident Knee Osteoarthritis: The MOST Study
Abstract Number: 645

The Combination of Metformin and 2-Deoxy-D-Glucose Normalizes CD4 T Cell Metabolism and Functions, and Reverse Disease in Murine Models of Lupus
Abstract Number: 2341

The Combination Therapy of Cell Cycle Regulation Therapy Combined and TNF Blockade Ameliorated the Established Arthritis
Abstract Number: 1110

The Comparative Efficacy of Kinesio Taping and Local Injection Therapy in Patients with Subacromial Impingement Syndrome
Abstract Number: 2562

The Comparative One-Year Drug Survival Rate of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid arthritis and ankylosing spondylitis; results from Turkbio Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].